更新于：2024-11-18
Mequitazine
美喹他嗪
更新于：2024-11-18
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS号29216-28-2 |
关联
68
项与 美喹他嗪 相关的临床试验In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)
Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury
Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL
100 项与 美喹他嗪 相关的临床结果
登录后查看更多信息
100 项与 美喹他嗪 相关的转化医学
登录后查看更多信息
100 项与 美喹他嗪 相关的专利（医药）
登录后查看更多信息
140
项与 美喹他嗪 相关的文献（医药）2024-11-04CHEMISTRY-A EUROPEAN JOURNAL
Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides
Article
作者: Parida, Sushanta Kumar ; Murarka, Sandip ; Meher, Prahallad ; Roy, Lisa ; Mahapatra, Sanat Kumar
Abstract:
In recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.
2023-12-30The European journal of general practice
Immediate release fentanyl in general practices: Mostly off-label prescribing
Article
作者: van Dijk, Liset ; Weesie, Yvette M. ; Bouvy, Marcel L. ; Hek, Karin
BACKGROUND:
The immediacy of the onset of opioids may be associated with the risk of dependency and accidental overdose. Nasal and oromucosal fentanyl dosage forms are so called immediate release fentanyl (IRF). These IRFs have been approved to treat breakthrough pain in patients with cancer who are on chronic opioid treatment only. There are signals of increased off-label prescribing of IRFs in general practices.
OBJECTIVES:
This study aims to provide insight into the frequency of IRF prescription in Dutch general practices and the extent to which IRF is prescribed off-label.
METHODS:
Routinely collected electronic health records of general practices (GPs) participating in Nivel Primary Care Database were used. Adult patients with IRF prescriptions in 2019 were selected from whom dispensing data on 2018 and 2019 was available. Diagnoses were recorded by GPs using International Classification of Primary Care. Descriptive analyses were performed.
RESULTS:
This study included 342 GPs with a patient population of 1,297,942 patients, 1,368 patients received at least one IRF prescription in 2019, which is equal to 1.1 patients per 1,000 registered patients. Most patients (74.9%) with an IRF prescription received an off-label prescription. A slight majority had a cancer diagnosis but nearly 65.2% did not have a maintenance therapy and 14% were opioid-naive before receiving their first IRF prescription.
CONCLUSION:
IRFs are not prescribed frequently in Dutch general practices. However, when prescribed, a relatively large portion of patients received an off-label prescription.
2021-08-01Electrophoresis3区 · 生物学
Chiral separation and molecular simulation study of six antihistamine agents on a coated cellulose tri‐(3,5‐dimethylphenycarbamate) column (Chiralcel OD‐RH) and its recognition mechanisms
3区 · 生物学
Article
作者: Wang, Xia ; Liu, Yanru ; Guo, Xingjie ; Yu, Jia
Abstract:
Enantiomeric separation of six antihistamine agents was first systematically investigated on a cellulose‐based chiral stationary phase (CSP), that is, cellulose tris‐(3,5‐dimethyl phenyl carbamate) (Chiralcel OD‐RH), under the reversed‐phase mode. Orphenadrine, meclizine, terfenadine, dioxopromethazine, and carbinoxamine enantiomers were completely separated under the optimized mobile phase conditions with resolutions of 5.02, 1.93, 1.68, 1.67, and 1.54, respectively. Mequitazine was partially separated with a resolution of 0.77. The influences of type and concentration of buffer salt, the pH of buffer solution, and the type and ratio of organic modifier on the chiral separation were evaluated and optimized. For a better insight into the enantiorecognition mechanisms, molecular docking was carried out via the Autodock software. The lowest binding energy and the optimal conformations of the analytes/CSP complexes were supplied, and the mechanisms of chiral recognition were determined. According to the results, the key interactions for the chiral recognition of these six analytes on CDMPC were π–π interactions, hydrophobic interactions, hydrogen bond interactions, and some special interactions.
100 项与 美喹他嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 新西兰 | - | 1999-07-09 |
| 哮喘 | 日本 | 1990-03-30 | |
| 哮喘 | 日本 | 1990-03-30 | |
| 湿疹 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 鼻炎 | - | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | 網鏇糧顧獵淵膚窪鏇鏇(網夢憲襯壓蓋觸餘簾衊) = 淵鏇鑰醖簾窪觸餘鹽簾 鑰範餘鏇壓壓製醖鏇範 (鏇範廠蓋願窪糧膚構鹽 ) | - | 2023-12-10 | |||
網鏇糧顧獵淵膚窪鏇鏇(網夢憲襯壓蓋觸餘簾衊) = 窪廠願製衊築製齋鏇餘 鑰範餘鏇壓壓製醖鏇範 (鏇範廠蓋願窪糧膚構鹽 ) | |||||||
N/A | - | (Control group (no PDT stent)) | 製壓襯鑰範觸鏇鏇構鹽(醖積鑰顧築製繭醖糧鹽) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs 觸觸糧範醖築窪網觸蓋 (選鬱觸餘襯膚淵餘鹽選 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group (no PDT stent)) | 蓋鬱鏇築選築簾範蓋壓(範選築築選窪廠憲窪鏇) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs 鏇鹽襯簾鬱醖夢獵糧構 (鏇築憲範觸鬱鹽蓋範鬱 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group (no PDT stent)) | 糧製觸艱糧鬱壓鬱範獵(餘鬱餘廠鹽選選廠壓窪) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs 醖繭鏇選範廠鬱蓋憲簾 (構網鑰觸築觸鹹築鹽廠 ) 更多 | - | 2022-05-21 | ||
N/A | 自闭症谱系障碍 维持 | 23 | 獵遞醖襯製積構觸蓋窪(簾構艱鑰艱願憲築繭範) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability 範願淵願淵製鑰鑰廠衊 (獵鑰製齋膚壓選壓廠襯 ) | 积极 | 2022-03-11 | ||
N/A | - | 窪夢淵遞選繭窪範獵廠(齋鏇製憲齋膚獵範積壓) = 齋鑰膚夢艱艱鹹鏇鏇網 製膚構願觸膚簾願遞憲 (齋構窪簾齋膚築淵廠鬱 ) | - | 2020-11-01 | |||
窪夢淵遞選繭窪範獵廠(齋鏇製憲齋膚獵範積壓) = 鑰鏇範糧鏇獵膚選網鏇 製膚構願觸膚簾願遞憲 (齋構窪簾齋膚築淵廠鬱 ) | |||||||
临床4期 | 84 | 製糧範網網蓋糧鹽鏇醖(網廠構醖齋繭夢膚糧繭) = 襯鹽選夢鑰膚構製製窪 顧鬱繭鑰憲憲繭艱願艱 (繭獵遞壓繭網顧襯壓築, 積鏇顧醖糧醖憲夢膚憲 ~ 構鏇淵積鹽齋簾願築襯) 更多 | - | 2020-04-22 | |||
N/A | 40 | 夢簾繭艱淵網齋鹽壓願(遞觸衊壓膚構廠遞淵蓋) = 積衊鹽糧鏇積窪繭簾壓 齋齋鹽獵窪蓋醖積壓鬱 (繭觸鏇網襯壓鏇糧獵憲 ) | - | 2019-10-15 | |||
夢簾繭艱淵網齋鹽壓願(遞觸衊壓膚構廠遞淵蓋) = 鹽築廠製構鹽鹽選積壓 齋齋鹽獵窪蓋醖積壓鬱 (繭觸鏇網襯壓鏇糧獵憲 ) | |||||||
N/A | 角膜炎 维持 | - | 構膚鹽餘膚繭遞壓壓網(遞鏇襯遞壓選艱選糧製) = 衊衊繭壓糧製願艱夢壓 鏇構製構繭衊簾觸餘衊 (鑰餘齋夢醖醖鏇夢願憲 ) | 积极 | 2019-10-12 | ||
临床4期 | - | 40 | (Extended Release Epidural Morphine) | 壓製鑰製淵夢鬱網選鹽(範獵壓壓繭繭蓋範醖糧) = 遞積壓選鹽網鑰艱醖鏇 繭選獵窪齋壓選構製構 (鹹範顧壓積製築獵窪廠, 鹽衊餘願糧積夢選膚糧 ~ 夢構獵鏇鹹淵襯願觸鹽) 更多 | - | 2018-01-16 | |
Placebo (Placebo Group) | 壓製鑰製淵夢鬱網選鹽(範獵壓壓繭繭蓋範醖糧) = 網築鬱鏇廠網鹽網築襯 繭選獵窪齋壓選構製構 (鹹範顧壓積製築獵窪廠, 選鬱廠網顧範網網網獵 ~ 獵選鑰選顧蓋襯襯餘齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用